Fig. 3: CDNF treatment enhanced expression of scavenger receptors on activated microglia/macrophages at the early stage of ICH.

A–D Figures show immunofluorescent staining of cells in hemorrhagic striatum with anti-CD11b (green), anti-CD163 (red) and counterstained with DAPI (blue). The insets show the hematoma edge in higher-magnification photomicrographs immunostained with CD11b and CD163 antibodies. Immunofluorescence pictures showing co-localization of CD163 and CD11b in the saline-treated perihematomal area at 1 d (A) and 3 d (B), respectively. C–E rhCDNF injections increased CD163 immunostaining in the peri-hematoma area at 1 d, but not at 3 d post-ICH, compared with saline group. **p < 0.01 Bonferroni’s multiple comparisons test, following two-way ANOVA [effect of treatment: F(1,32) = 5.026, P = 0.03]. F–J WB bands of CD163, CD36, CD91, and GAPDH at different time points post-ICH. G Increased the level of CD163 in the rhCDNF-treated hemorrhagic striatum at 1 d but not at 3 d post-ICH. **P < 0.001, Bonferroni’s multiple comparisons test, following two-way ANOVA [effect of treatment: F(1,12) = 44.52, P < 0.001]. H, I Increased levels of cell surface CD36 and intracellular CD36 were detected in rhCDNF-treated hemorrhagic striatum at 1 d post-ICH. *p < 0.05, **p < 0.01, Bonferroni’s multiple comparisons test, following two-way ANOVA [effect of treatment: F(1,18) = 30.2, P < 0.001. J rhCDNF treatment did not increase the level of CD91 in the hemorrhagic striatum, compared to a saline-treated group post-ICH. The mean ± SEM of three independent experiments is shown. Scale bars: A, B: 1000 µl, C, D: 50 µl.